FSD Pharma Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div yield, %

—

Shrs. gr., 5y

77.73%

Rev. gr., 5y

69.97%

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

FSD Pharma Inc. functions as a biotechnology firm dedicated to the discovery and advancement of pharmaceutical products. Its main drug candidate, FSD201, is a palmitoylethanolamide currently undergoing development for addressing inflammatory conditions. Furthermore, the company is pursuing research and development into Lucid-Psych, a molecular compound targeting mental health challenges, and Lucid-MS, another molecular compound designed for neurodegenerative illnesses. FSD Pharma Inc. maintains its corporate headquarters in Toronto, Canada.

URL

https://www.fsdpharma.com/

IPO date

May 29, 2018

Employees

Domiciled in

Incorporated in

Valuation

No data to show